Lower-Risk Myelodysplastic Syndrome (MDS) Patients Exhibit Diminished Proteasome Proteolytic Activity and High Intracellular Reactive Oxygen Species (ROS) Levels

• Published in: Curēus (Palo Alto, CA) Vol. 15; no. 12; p. e49843
• Main Authors: Zafeiropoulou, Kalliopi, Kalampounias, Georgios, Alexis, Spyridon, Androutsopoulou, Theodosia, Katsoris, Panagiotis, Symeonidis, Argiris
• Format: Journal Article
• Language: English
• Published: United States Springer Nature B.V 02.12.2023; Cureus
• Subjects: Antibodies; Blood & organ donations; Bone marrow; Hematology; Inhibitor drugs; Oncology; Oxidative stress; Peptides; Proteins; Reactive oxygen species; Stem cells; Targeted cancer therapy; Therapeutics; United States > US; Texas; Massachusetts; Japan; Germany; ipss-r; ubiquitin-proteasome system; myelodysplastic syndromes; reactive oxygen species; proteasome inhibitors; bortezomib; cd34 positive; acute myeloid leukemia (aml); bone marrow; oxidative stress

Myelodysplastic syndromes (MDS) constitute a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis and an elevated risk of transformation to acute myeloid leukemia (AML). Available disease-modifying treatment approaches are limited. The ineffectiv...